NCT07618052|Not Yet RecruitingDMC
Loading search results
Sponsor study identifier
interventional
420
1 country
1
Study Start
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
A multicenter, randomized, open-label, blinded-endpoint trial with a concurrent prospective observational cohort to compare bailout intracranial angioplasty or stenting versus standard therapy on functional outcome, stroke recurrence, and mortality in patients with acute intracranial atherosclerotic stenosis-related large vessel occlusion after thrombectomy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 25, 2026
Actual (reported)June 1, 2026
Actual (reported)June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The primary endpoint is the mRS score at 90 (±7) days after randomization (or after enrollment), analyzed as an ordinal variable
The modified Rankin scale (mRS) ranged from 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability,5 severe disability, and 6 death.
90±7 days after randomization (or after enrollment)
The proportion of mRS 0-1, 0-2 and 0-3 at 90 (±7) days
90±7 days after randomization (or after enrollment)
The rate of stroke recurrence in the target vessel territory within 90 (±7) days
90±7 days after randomization (or after enrollment)
Bailout Angioplasty or Stenting (BAOS) Group
Standard Ttherapy Group
Balloon angioplasty and/or stent placement for residual severe stenosis (≥70%) after successful thrombectomy; combined with medical management (intravenous tirofiban, followed by dual antiplatelet therapy with aspirin 100 mg/day and clopidogrel 75 mg/day for 90 days, then single antiplatelet therapy thereafter; and cerebrovascular risk factor management).
Endovascular thrombectomy performed according to guideline recommendations, without additional endovascular intervention; combined with medical management (intravenous tirofiban as needed, dual antiplatelet therapy with aspirin 100 mg/day and clopidogrel 75 mg/day for 90 days, then single antiplatelet therapy thereafter; and cerebrovascular risk factor management).
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
Feng Gao, MD
Beijing Tiantan Hospital
First Submitted
May 25, 2026
First Posted
June 1, 2026
Study Start
June 1, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
NIHSS score at 24 (±6/+12) hours
24 (-6/+12) hours after randomization (or after enrollment)
European Five Dimensional Health Scale Level 5 (EQ-5D-5L) score at 90±7 days
90±7 days after randomization (or after enrollment)
Patency of the target vessel at 24 (±6/+12) hours after the procedure, as confirmed by CTA, MRA, DSA, or TCD
24 (-6/+12) hours after randomization (or after enrollment)
The rate of any Symptomatic intracranial hemorrhage (sICH) defined as the Heidelberg classification within 24 hours
24 (-6/+12) hours after randomization (or after enrollment)
The rate of all-cause mortality within 90 days
90±7 days after randomization (or after enrollment)
The rate of any intracranial hemorrhage identified by CT or MRI imaging within 24 hours after randomization
24 (-6/+12) hours after randomization
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
June 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
June 1, 2026
Record last verified: 2026-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: